India Takes a Crucial Step in Dengue Prevention, But Challenges Lie Ahead

The approval of Takeda’s Qdenga as the first dengue vaccine in India marks a significant development in the country’s fight against this mosquito-borne disease. With 14.4 million reported cases and 11,201 deaths worldwide in 2024, including 232,425 cases and 233 deaths in India, effective prevention measures have never been more pressing.

Dengue has become a growing concern in India over the past two decades, with reported cases rising by an astonishing 11-fold. The approval of Qdenga is a crucial step towards addressing this public health crisis, but it comes with its own set of challenges. One key concern surrounding dengue vaccines is safety, particularly in regions where the disease is endemic.

Sanofi’s Dengvaxia has been associated with an increased risk of severe dengue in some individuals who have not previously been infected with the virus. Regulatory bodies have responded by imposing strict guidelines on its use, including pre-vaccination testing. Qdenga, on the other hand, has shown promising results in clinical trials, with an efficacy rate of 80.2% against confirmed dengue cases one year after the second dose.

However, experts caution that Qdenga will not prevent outbreaks as long as the mosquito vector continues to circulate. This highlights the need for a multi-faceted approach to addressing dengue, including effective vaccination programs, improved surveillance, and targeted interventions to reduce mosquito populations.

The lengthy development process for dengue vaccines remains a significant challenge for vaccine makers. Hyderabad-based Indian Immunologicals Ltd (IIL) is developing its own dengue vaccine candidate and preparing to begin mid-stage clinical trials. IIL’s managing director, K. Anand Kumar, acknowledges the challenges of addressing safety concerns arising from earlier dengue vaccines and identifying trial participants who have not previously been infected with dengue or related viruses.

The approval of Qdenga marks a significant milestone in India’s vaccine landscape but also highlights the need for continued investment in research and development. As the country looks to boost its manufacturing capacity to meet growing demand, it must prioritize post-marketing safety data collection to ensure that Qdenga is used safely and effectively.

The Indian government has partnered with Takeda Biopharmaceuticals India and Biological E to expand production of Qdenga, increasing access to this critical vaccine. However, more needs to be done to address the underlying causes of dengue outbreaks, including improving healthcare infrastructure, enhancing surveillance, and promoting behavioral changes among at-risk populations.

As Qdenga becomes available in India in the first half of 2027, policymakers must prioritize public awareness campaigns to educate citizens about the vaccine’s benefits and limitations. This will be crucial in building trust and ensuring that the vaccine is used effectively to prevent dengue outbreaks.

The Indian government’s commitment to improving healthcare infrastructure and enhancing surveillance will be crucial in reducing the burden of dengue on the country’s healthcare system. By combining vaccination efforts with targeted interventions, policymakers can make significant strides towards controlling dengue outbreaks and protecting public health.